| Project/Area Number |
15K20090
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
FURUKAWA JUNYA 神戸大学, 医学部附属病院, 講師 (20448179)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 腎細胞癌 / 標的治療 / Hedgehog経路 / 分子標的薬 / 治療抵抗性 / Hedgehogシグナル / Gli / sunitinib / resistance |
|---|
| Outline of Final Research Achievements |
This study reports that retrospectively reviewed clinicopathological data from a total of 39 consecutive Japanese patients undergoing radical nephrectomy, who were diagnosed with metastatic clear cell renal cell carcinoma and subsequently treated with sunitinib as a first-line therapy, and evaluated whether expression levels of Hedgehog signaling-related proteins and major molecular targets of sunitinib in primary RCC specimens could be used as a reliable prognostic factor for this cohort of patients. We concluded that GLI2 appeared to be associated with the prognosis of Japanese patients who were treated with sunitinib as a first-line therapy for m-ccRCC. Furthermore, GLI2 is involved in the acquisition of resistance to sunitinib in RCC.
|
